The 13 most recent market catalysts affecting $TLX, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Sep 23, 2026
Corporate Catalyst
Bearish
Impact 55
Wedbush Reiterates Outperform on Telix Pharmaceuticals, Maintains $22 Price Target
Wedbush analyst David Nierengarten has reaffirmed his 'Outperform' rating and $22 price target for Telix Pharmaceuticals. This action signals that the analyst's positive outlook on…
Sep 21, 2026
Corporate Catalyst
Neutral
Impact 95
Telix Makes $1.65 Billion Bet on ITM to Build a Radiopharma Powerhouse
Telix Pharmaceuticals is acquiring ITM Isotope Technologies Munich SE for $1.65 billion in a move to become a vertically integrated leader in radiopharmaceuticals. This acquisition…
Sep 21, 2026
Corporate Catalyst
Neutral
Impact 95
Reported September 20, 2026: 'Australia's Telix Pharma Agrees To Buy Germany's ITM Isotope For About $1.65B'
Telix Pharma has agreed to acquire ITM Isotope for approximately $1.65 billion, as detailed in the linked press release. This is a major M&A event in the radiopharmaceutical sector…
Sep 14, 2026
Corporate Catalyst
Bearish
Impact 55
Wedbush Reiterates Outperform on Telix Pharmaceuticals, Maintains $22 Price Target
This 8-K filing discloses that Wedbush analyst David Nierengarten has reiterated an 'Outperform' rating and maintained a $22 price target for Telix Pharmaceuticals. This action sig…
Sep 14, 2026
Corporate Catalyst
Bullish
Impact 85
FDA Approves Telix Pharma’s NDA For Pixclara, Amino Acid Positron Emission Tomography Drug For Imaging Gliomas
Telix Pharmaceuticals has secured FDA approval for Pixclara, its novel FET-PET imaging drug for gliomas. This is a significant development as Pixclara is the first FDA-approved pro…
Sep 2, 2026
Corporate Catalyst
Bullish
Impact 65
Telix Pharmaceuticals shares are trading higher after HC Wainwright & Co. reiterated its Buy rating on the stock and maintained a $20 price target.
The reiterated 'Buy' rating and maintained price target from HC Wainwright & Co. acts as a positive corporate catalyst for Telix Pharmaceuticals. This analyst endorsement provides …
Sep 2, 2026
Corporate Catalyst
Neutral
Impact 55
HC Wainwright & Co. Reiterates Buy on Telix Pharmaceuticals, Maintains $20 Price Target
HC Wainwright & Co. analyst Robert Burns has reiterated a 'Buy' rating and maintained a $20 price target for Telix Pharmaceuticals. This action signals continued analyst confidence…
Aug 20, 2026
Corporate Catalyst
Bearish
Impact 55
Wedbush Reiterates Outperform on Telix Pharmaceuticals, Maintains $22 Price Target
This 8-K filing discloses that Wedbush analyst David Nierengarten has reiterated an 'Outperform' rating and maintained a $22 price target for Telix Pharmaceuticals. This action sig…
Aug 20, 2026
Corporate Catalyst
Bullish
Impact 75
Reported Earlier, Telix Pharmaceuticals Guides FY 2026 Revenue Of $950M-$970M, Total Income Above $1B, Reaffirms R&D Guidance Of $230M-$270M
Telix Pharmaceuticals has released updated financial guidance for FY 2026, projecting robust revenue and total income figures, with revenue expected to be at the upper end of its p…
Aug 20, 2026
Corporate Catalyst
Bullish
Impact 85
Reported Earlier, Telix Pharmaceuticals Reports H1 2026 Revenue Of $477M, Up 22% YoY, And Profit After Tax Of $38M Versus $2M Loss
The reported H1 2026 results for Telix Pharmaceuticals are highly positive, showcasing substantial revenue growth and a significant turnaround from a loss to a profit. This indicat…
Jul 21, 2026
Corporate Catalyst
Bullish
Impact 92
Reported Earlier, Telix FY2026 Revenue Guidance $950M-$970M Plus $40M Regeneron Payment, Total Expected Above $1B
This headline is a major positive catalyst for Telix (TLX). The FY2026 revenue guidance of over $1 billion, including a significant Regeneron payment, far surpasses previous expect…
Jul 21, 2026
Corporate Catalyst
Bullish
Impact 75
Reported Earlier, Telix Q2 Revenue $247M Up From $204M, With Precision Medicine Up 30% YoY
The headline highlights significant revenue growth for Telix, driven by its precision medicine segment. This indicates strong operational execution and market demand for their prod…
Jul 20, 2026
Corporate Catalyst
Neutral
Impact 65
Telix Pharmaceuticals Announces That The First Patient Has Been Dosed With TLX250-Tx In The LUTEON Study
Telix Pharmaceuticals has announced that the first patient has been dosed with TLX250-Tx in the LUTEON study, a Phase 3 clinical trial for clear cell renal cell carcinoma (ccRCC). …
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.